We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Research Letter | Health Care Reform

Cancer Drugs Approved on the Basis of a Surrogate End Point and Subsequent Overall Survival An Analysis of 5 Years of US Food and Drug Administration Approvals

Chul Kim, MD, MPH1; Vinay Prasad, MD, MPH2
[+] Author Affiliations
1Medical Oncology Service, National Cancer Institute, National Institutes of Health, Bethesda, Maryland
2Division of Hematology and Medical Oncology, Knight Cancer Center, Oregon Health and Sciences University, Portland
JAMA Intern Med. 2015;175(12):1992-1994. doi:10.1001/jamainternmed.2015.5868.
Text Size: A A A
Published online


This review of approvals of cancer drugs based on a surrogate end point by the US Food and Drug Administration assesses the postmarketing findings for overall survival.

Most contemporary approvals of new cancer drugs are made on the basis of a surrogate end point, such as response rate or progression-free survival (PFS).1 When the approval is based on a surrogate end point, subsequent studies are advised and often obligated to clarify the drug’s effect on overall survival. One such drug is bevacizumab, which received accelerated approval on the basis of PFS for patients with metastatic breast cancer. Later findings revealed no improvement in overall survival and significant toxicity, which required a removal of marketing authorization.2

Figures in this Article

First Page Preview

View Large
First page PDF preview


Place holder to copy figure label and caption
Figure 1.
Oncology Drug Approvals Made on the Basis of a Surrogate End Point During the Study Period

The study period extends from January 1, 2008, through December 31, 2012. ALK indicates anaplastic lymphoma kinase; ALL, acute lymphoblastic leukemia; BCC, basal cell carcinoma; CLL, chronic lymphocytic leukemia; CML, chronic myeloid leukemia; CTCL, cutaneous T-cell lymphoma; DFS, disease-free survival; ERBB2 (formerly HER2 or HER2/neu), erb-b2 receptor tyrosine kinase 2; GIST, gastrointestinal stromal tumor; NET, neuroendocrine tumor; NHL, non-Hodgkin lymphoma; NSCLC, non–small cell lung cancer; PFS, progression-free survival; Ph, Philadelphia chromosome; RCC, renal cell carcinoma; and RR, response rate.

Graphic Jump Location
Place holder to copy figure label and caption
Figure 2.
Overall Survival Results for Cancer Drug Approvals Granted on the Basis of a Surrogate End Point

Exact numbers of approvals depicted in this graph are given in the Results section.

Graphic Jump Location




Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

9 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.

See Also...
Articles Related By Topic
Related Collections
PubMed Articles